刚果(金)东部冲突后地区耐利福平结核的患病率、预测因素与治疗转归
该回顾性省级队列研究分析了2012年2月至2017年6月南基伍省经Xpert MTB/RIF确诊的1535例结核患者,发现11%为耐利福平结核。涂片阳性、复治和既往结核史是独立预测因素,超过45%的耐利福平患者无既往结核史。
要点
- 在冲突后地区,Xpert确诊的结核患者中耐利福平结核患病率为11%。
- 涂片阳性、复治和既往结核史是耐利福平结核的独立预测因素。
核心结论
- 在冲突后地区,尽管耐利福平结核患病率较高,仍可获得较好的治愈率。
- 扩大Xpert应用、及时启动更短更安全高效的MDR-TB方案及治疗依从性支持对优化结局至关重要。
研究设计与样本
- 回顾性省级队列研究,纳入2012年2月至2017年6月在南基伍省经痰涂片和Xpert MTB/RIF评估的成人和儿童肺结核患者。
- 使用多变量logistic回归、Kaplan-Meier估计和多变量Cox回归评估耐利福平结核及治疗失败/死亡的独立预测因素。
主要发现
- 1535例Xpert阳性结核患者中,11%为耐利福平结核。
- 耐利福平结核的独立预测因素包括涂片阳性(aOR 2.42,95%CI 1.63-3.59)、复治(aOR 4.92,95%CI 2.31-10.45)和每增加一次既往结核史(aOR 1.77,95%CI 1.01-3.10)。
- 超过45%的耐利福平结核患者无既往结核病史或治疗史。
- 从Xpert诊断到启动耐利福平结核治疗的中位时间为12天(IQR 3-60.2)。
临床怎么用
- 在冲突后地区应扩大Xpert MTB/RIF的应用以检出耐利福平结核。
- 对耐利福平结核患者应优先采用更短、更安全、高效的MDR-TB方案并加强治疗依从性支持。
- 确保直接面视下治疗的实施并监测严重药物不良事件以降低治疗失败/死亡风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Multidrug-resistant tuberculosis (MDR-TB) jeopardizes global TB control. The prevalence and predictors of Rifampicin-resistant (RR) TB, a proxy for MDR-TB, and the treatment outcomes with standard and shortened regimens have not been assessed in post-conflict regions, such as the South Kivu province in the eastern Democratic Republic of the Congo (DRC). We aimed to fill this knowledge gap and to inform the DRC National TB Program. METHODS: of adults and children evaluated for pulmonary TB by sputum smear microscopy and Xpert MTB/RIF (Xpert) from February 2012 to June 2017. Multivariable logistic regression, Kaplan-Meier estimates, and multivariable Cox regression were used to assess independent predictors of RR-TB and treatment failure/death. RESULTS: Of 1535 patients Xpert-positive for TB, 11% had RR-TB. Independent predictors of RR-TB were a positive sputum smear (adjusted odds ratio [aOR] 2.42, 95% confidence interval [CI] 1.63-3.59), retreatment of TB (aOR 4.92, 95% CI 2.31-10.45), and one or more prior TB episodes (aOR 1.77 per episode, 95% CI 1.01-3.10). Over 45% of RR-TB patients had no prior TB history or treatment. The median time from Xpert diagnosis to RR-TB treatment initiation was 12 days (interquartile range 3-60.2). Cures were achieved in 30/36 (83%) and 84/114 (74%) of patients on 9- vs 20/24-month MDR-TB regimens, respectively (P = .06). Predictors of treatment failure/death were the absence of directly observed therapy (DOT; adjusted hazard ratio [aHR] 2.77, 95% CI 1.2-6.66) and any serious adverse drug event (aHR 4.28, 95% CI 1.88-9.71). CONCLUSIONS: Favorable RR-TB cure rates are achievable in this post-conflict setting with a high RR-TB prevalence. An expanded Xpert scale-up; the prompt initiation of shorter, safer, highly effective MDR-TB regimens; and treatment adherence support are critically needed to optimize outcomes.
引用
- Bulabula ANH, Nelson JA, Musafiri EM, et al. Prevalence, Predictors, and Successful Treatment Outcomes of Xpert MTB/RIF-identified Rifampicin-resistant Tuberculosis in Post-conflict Eastern Democratic Republic of the Congo, 2012-2017: A Retrospective Province-Wide Cohort Study. Clin Infect Dis. 2019. PMID: 30759187. doi:10.1093/cid/ciy1105
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。